Clinical Trial Update: A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis

View source ↗

Summary

A long-term observational registry is underway to observe the effects of nintedanib in people with scleroderma-related interstitial lung disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease | Status: ACTIVE_NOT_RECRUITING